Page 6 of 8, showing 50 records out of 368 total, starting on record 251, ending on 300
| Publication |
Category |
Year |
|
96. Labrie, C., Flamand, M., Bélanger, A., Labrie, F. (1996) High bioavailability of DHEA administered percutaneously in the rat. J. Endocrinol., 150: S107-S118. |
Prostate Cancer |
1996 |
|
97. Labrie, F., Bélanger, A., Cusan, L., Labrie, C., Simard, J., Luu-The, V., Gomez, J.L., Diamond, P., Candas, B. (1996) History of LHRH agonist and combination therapy in prostate cancer. Endocrine-Related Cancer, 3: 243-278. |
Prostate Cancer |
1996 |
|
98. Labrie, F., Bélanger, A., Simard, J., Luu-The, V., Labrie, C., Cusan, L., Gomez, J., Diamond, P., Candas, B. (1996) Sources d'androgènes chez l'homme et traitement hormonal du cancer de la prostate (Chapter 16), in: Belaisch, J., Drodowsky, M.A. et Vermeulen, A., eds: Progrès en Andrologie: Endocrinologie Masculine, Doin, pp 215-229. |
Prostate Cancer |
1996 |
|
99. Labrie, F., Candas, B., Cusan, L., Diamond, P., Gomez, J.L. (1996) Antiandrogen story erred [Letter to the Editor]. The Medical Post, 32: |
Prostate Cancer |
1996 |
|
100. Labrie, F., Candas, B., Cusan, L., Gomez, J.L., Diamond, P., Suburu, R., Lemay, M. (1996) Diagnosis of advanced or non-curable prostate cancer can be practically eliminated by prostate-specific antigen. Urology, 47: 212-217. |
Prostate Cancer |
1996 |
|
101. Labrie, F., Cusan, L., Dupont, A., Gomez, J.-L., Simard, J., Luu-The, V., Pelletier, G., Labrie, C., Bélanger, A. (1996) Androgen receptor antagonists (Chapter 28), in: Adashi, E.Y., Rock, J.A. et Rosenwaks, Z., eds: Reproductive Endocrinology, Surgery and Technology, Philadelphia, Lippincott-Raven Publishers, pp 559-583. |
Prostate Cancer |
1996 |
|
102. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Bélanger, A., Candas, B. (1996) Combination therapy in localized prostate cancer (Chapter 4), in: Schroder, F.H., ed. Recent Advances in Prostate Cancer and BPH, Parthenon Publishing, pp 31-43. |
Prostate Cancer |
1996 |
|
103. Labrie, F., Dupont, A., Cusan, L., Gomez, J.L., Surubu, R., Diamond, P. (1996) Combination therapy with Flutamide: The therapy of choice from early to advanced stages of prostate cancer, in: Denis, L., ed. Antiandrogens in Prostatic Cancer, Italy, European School of Oncology, pp 63-74. |
Prostate Cancer |
1996 |
|
104. Labrie, F., Simard, J., Luu-The, V., Labrie, C., Bélanger, A. (1996) Adrenal androgens are responsible for 40-50% and not 5-10% of total prostatic androgens in 65-year-old men: intracrinology, in First International Consultation on Prostate Cancer, Monaco, pp Published on CD-ROM. |
Prostate Cancer |
1996 |
|
105. Luo, S., Martel, C., Leblanc, G., Candas, B., Singh, S.M., Labrie, C., Simard, J., Bélanger, A., Labrie, F. (1996) Relative potencies of flutamide and casodex: preclinical studies. Endocrine-Related Cancer, 3: 229-241. |
Prostate Cancer |
1996 |
|
106. Vaillancourt, L., Têtu, B., Fradet, Y., Dupont, A., Gomez, J., Cusan, L., Suburu, R.E., Diamond, P., Candas, B., Labrie, F. (1996). Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma: a randomized study. Am. J. Surg. Pathol., 20: 86-93. |
Prostate Cancer |
1996 |
|
107. van der Kwast, T.H., Tetu, B., Fradet, Y., Dupont, A., Gomez, J., Cusan, L., Diamond, P., Labrie, F. (1996) Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy. Prostate, 28: 227-231. |
Prostate Cancer |
1996 |
|
81. Labrie, F. (1997) Flutamide plus castration in patients with previously untreated prostate cancer [Letter to the Editor re: Noldus et al. 47: 713-8, 1996]. Urology, 50: 479. |
Prostate Cancer |
1997 |
|
82. Labrie, F., Candas, B., Cusan, L., Gomez, J.L., Diamond, P., Lemay, M. (1997) Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen [Letter to the Editor: Reply to Brown and Feuer re 47: 212-7, 1996]. Urology, 49: 306-307. |
Prostate Cancer |
1997 |
|
83. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Bélanger, A., Candas, B. (1997) Long-term neoadjuvant and adjuvant combined androgen blockade is needed for efficacy of treatment in localized prostate cancer. Mol. Urol., 1: 253-261. |
Prostate Cancer |
1997 |
|
84. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Suburu, R., Lemay, M., Tetu, B., Fradet, Y., Bélanger, A., Candas, B. (1997) Neoadjuvant hormonal therapy: the Canadian experience. Urology, 49: 56-64. |
Prostate Cancer |
1997 |
|
85. Labrie, F., Simard, J., Candas, B. (1997) Reply by the authors to: Editorial comment of: Comparison of in vitro effects of the pure antiandrogens OH-Flutamide, Casodex and Nilutamide on androgen-sensitive parameters [Reply to the authors/P.F. Schellhammer]. Urology, 49: 586-589. |
Prostate Cancer |
1997 |
|
86. Labrie, F., Simard, J., Singh, S.M., Candas, B. (1997) Estimated potency of Casodex: A problematic design [Letter to the Editor re Schellhammer et al. 45: 745-52, 1995]. Urology, 50: 309-313. |
Prostate Cancer |
1997 |
|
87. Laverdiere, J., Gomez, J.L., Cusan, L., Suburu, R.E., Diamond, P., Lemay, M., Candas, B., Fortin, A., Labrie, F. (1997) Beneficial effect of combination therapy administered prior to, during and following external beam radiation therapy in localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 37: 247-252. |
Prostate Cancer |
1997 |
|
88. Luo, S., Chen, C., Labrie, C., Candas, B., Singh, S.M., Labrie, F. (1997) Daily dosing with Flutamide or Casodex exerts maximal antiandrogenic activity. Urology, 50: 913-919. |
Prostate Cancer |
1997 |
|
89. Simard, J., Labrie, F. (1997) Recent advances in androgen receptor research: relative potencies of pure antiandrogens and implications for prostate cancer therapy, in: New diagnostic and treatment modalities in prostate cancer, Project in Knowledge, pp 15-23. |
Prostate Cancer |
1997 |
|
90. Simard, J., Singh, S.M., Labrie, F. (1997) Comparison of in vitro effects of the pure antiandrogens OH-Flutamide, Casodex and Nilutamide on androgen-sensitive parameters. Urology, 49: 580-589. |
Prostate Cancer |
1997 |
|
73. Chen, C., Li, X., Singh, S.M., Labrie, F. (1998) Activity of 17beta-(N-alkyl/arylformamido)- and 17beta-[(N-alkyl/aryl) alkyl/arylamido]-4-methyl-4-aza-5alpha-androstan-3-ones as 5alpha-reductase inhibitors in the hamster flank organ and ear. J. Invest. Dermatol., 111: 273-278. |
Prostate Cancer |
1998 |
|
74. Eeles, R.A., Durocher, F., Edwards, S., Teare, D., Badzioch, M., Hamoudi, R., Gill, S., Biggs, P., Dearnaley, D., Ardern-Jones, A., Dowe, A., Shearer, R., McLennan, D.L., Norman, R.L., Ghadirian, P., Aprikian, A., Ford, D., Amos, C., King, T.M., The Cancer Research Campaign/British Prostate Group U.K. Familial Prostate Cancer Study Collaborators, Labrie, F., Simard, J., Narod, S.A., Easton, D., Foulkes, W.D. (1998) Linkage analysis of chromosome 1q markers in 136 prostate cancer families. Am. J. Hum. Genet, 62: 653-658. |
Prostate Cancer |
1998 |
|
75. Labrie, F. (1998) Combined androgen blockade and treatment of localized prostate cancer: a real hope when approaching the year 2000. Endocrine-Related Cancer, 5: 341-351. |
Prostate Cancer |
1998 |
|
76. Labrie, F. (1998) Optimizing combined androgen blockade in prostate cancer, in: Belldegrun, A., Kirby, R.S. et Oliver, R.T.D., eds: New Perspectives in Prostate Cancer, England, ISIS Medical Media, pp 293-311. |
Prostate Cancer |
1998 |
|
77. Labrie, F., Bélanger, A., Luu-The, V., Labrie, C., Simard, J., Cusan, L., Gomez, J.L., Candas, B. (1998) DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging. Steroids, 63: 322-328. |
Prostate Cancer |
1998 |
|
78. Pelletier, G., Luu-The, V., Huang, X.F., Lapointe, H., Labrie, F. (1998) Localization by in situ hybridization of steroid 5alpha-reductase isozyme gene expression in the human prostate and preputial skin. J. Urol., 160: 577-582. |
Prostate Cancer |
1998 |
|
79. Têtu, B., Van der kwast, T., Fradet, Y., Candas, B., Gomez, J.L., Cusan, L., Labrie, F. (1998) Morphologic effects of neoadjuvant hormone therapy on prostate cancer. Mol. Urol., 2: 103-107. |
Prostate Cancer |
1998 |
|
80. van der Kwast, T., Têtu, B., Suburu, E.R., Gomez, J., Lemay, M., Labrie, F. (1998) Cycling activity of benign prostatic epithelial cells during long-term androgen blockade: evidence for self-renewal of luminal cells. J. Pathol., 186: 406-409. |
Prostate Cancer |
1998 |
|
56. Boivin, R.P., Poirier, D., Labrie, F. (1999) 17alpha-alkan (or alkyn) amide derivatives of estradiol as inhibitors of steroid-sulfatase activity. Steroids, 64: 825-833. |
Prostate Cancer |
1999 |
|
58. Kelloff, G.J., Lieberman, R., Brawer, M.K., Crawford, E.D., Labrie, F., Miller, G.J. (1999) Strategies for chemoprevention of prostate cancer. Prostate Cancer and Prostatic Diseases, 2: 27-33. |
Prostate Cancer |
1999 |
|
59. Labrie, F. (1999) Combined androgen blockade: its unique efficacy for the treatment of localized prostate cancer, in: De Vita, V.T., Hellman, S. et Rosenberg, S.A., eds: Cancer: Principles and Practice of Oncology, Philadelphia, Lippincott-Raven, pp 1-9. |
Prostate Cancer |
1999 |
|
60. Labrie, F. (1999) Prostate cancer: Endocrinology of prostate cancer-intracrinology, in: Pinchera, A., Bertega, X., Binder, C., Fischer, J. et Braverman, L., eds: Textbook of Clinical Endocrinology, Milan, Italy, McGraw-Hill Libri Italia Srl, pp 13-16. |
Prostate Cancer |
1999 |
|
61. Labrie, F., Bélanger, A., Simard, J., Luu-The, V., Labrie, C., Lin, S.-X., Candas, B., Cusan, L. (1999) Impact de l'intracrinologie dans la thérapeutique et la prévention des cancers du sein et de la prostate et de la ménopause, in: Guérité, N. et Leclère, J., eds: Mises au point cliniques d'endocrinologie, nutrition et métabolisme 1999, Paris, France, Les Éditions de Médecine Pratique, pp 169-204. |
Prostate Cancer |
1999 |
|
62. Labrie, F., Candas, B. (1999) Bicalutamide versus Flutamide in combination therapy [Letter to the Editor re: Schellhammer et al. 50: 330-336, 1997]. Urology, 53: 662-663. |
Prostate Cancer |
1999 |
|
63. Labrie, F., Candas, B. (1999) The Quebec study shows a 69% decrease in prostate cancer death [Authors' Response to comment of Alexander and Prescott on Prostate 38 (2): 83-91, 1999]. Prostate, 40: 137. |
Prostate Cancer |
1999 |
|
64. Labrie, F., Candas, B. (1999) Various statistical analyses indicate a marked reduction of prostate cancer death in the Quebec trial [Authors' Response to comment of Boer and Schroder on Prostate 38 (2): 83-91, 1999]. Prostate, 40: 132-134. |
Prostate Cancer |
1999 |
|
65. Labrie, F., Candas, B., Dupont, A., Cusan, L., Gomez, J.L., Suburu, R.E., Diamond, P., Lévesque, J., Bélanger, A. (1999) Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate, 38: 83-91. |
Prostate Cancer |
1999 |
|
66. Labrie, F., Cusan, J., Gomez, J., Levesque, J., Candas, B. (1999) Screening and treatment of localized prostate cancer decreases mortality: first analysis of the first prospective and randomized study on prostate cancer screening. Society of the Study of the Aging Male, 2: 33-43. |
Prostate Cancer |
1999 |
|
67. Labrie, F., Cusan, L., Gomez, J.-L., Bélanger, A., Candas, B. (1999) Long-term combined androgen blockade alone for localized prostate cancer. Mol. Urol., 3: 217-226. |
Prostate Cancer |
1999 |
|
68. Labrie, F., Simard, J., Coquet, A., Leblanc, G., Candas, B. (1999) Relative potency of bicalutamide (Casodex) and Flutamide (Eulexin) [Letter to the Editor: Reply by the authors re: 50: 913-919, 1997]. Urology, 54: 195-197. |
Prostate Cancer |
1999 |
|
70. van der Kwast, T.H., Labrie, F., Têtu, B. (1999) Persistence of high-grade prostatic intra-epithelial neoplasia under combined androgen blockade therapy. Hum. Pathol., 30: 1503-1507. |
Prostate Cancer |
1999 |
|
71. van der Kwast, T.H., Labrie, F., Têtu, B. (1999) Prostatic intraepithelial neoplasia and endocrine manipulation. Eur. Urol., 35: 508-510. |
Prostate Cancer |
1999 |
|
72. van der Kwast, T.H., Têtu, B., Candas, B., Gomez, J.-L., Cusan, L., Labrie, F. (1999) Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: three versus six months of endocrine therapy. Urology, 53: 523-529. |
Prostate Cancer |
1999 |
|
806. El-Alfy, M., Luu-The, V., Huang, X.F., Berger, L., Labrie, F., Pelletier, G. (1999) Localization of type 5 17beta-hydroxysteroid dehydrogenase, 3beta-hydroxysteroid dehydrogenase and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry. Endocrinology, 140: 1481-1491. |
Prostate Cancer |
1999 |
|
4726. Pelletier, G., Luu-The, V., Tetu, B., Labrie, F. (1999) Immunocytochemical localization of type 5 17beta-hydroxysteroid dehydrogenase in human reproductive tissues. J. Histochem Cytochem., 47: 731-738. |
Prostate Cancer |
1999 |
|
44. Candas, B., Cusan, L., Gomez, J.-L., Diamond, P., Suburu, R.E., Lévesque, J., Brousseau, G., Bélanger, A., Labrie, F. (2000) Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer. Prostate, 45: 19-35. |
Prostate Cancer |
2000 |
|
45. El-Alfy, M., Pelletier, G. Hermo, L.S., Labrie, F. (2000) Unique features of the basal cells of human prostate epithelium. Microsc. Res. Tech., 51: 436-446. |
Prostate Cancer |
2000 |
|
46. Labrie, F. (2000) Screening and early hormonal treatment of prostate cancer are accumulating strong evidence and support. Prostate, 43: 214-222. |
Prostate Cancer |
2000 |